Skip to content

Collegium Pharmaceutical, Inc

COLL· NasdaqCore metricsCIK 1267565

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · +0.83%
Market cap
$776.11M
31.08M shares
Filings
872
$216.34M
Q3 2026+23.6% FY25 yoy
$21.76M
Q3 2026−9.1% FY25 yoy
$28.72M
Q3 2026+5.7% FY25 yoy
$213.93M
Q3 2026derived+61.1% FY25 yoy
$0.60
Q3 2026−7.0% FY25 yoy
$144.80M
Q3 2026+227.7% FY25 yoy
$776.11M
20.3×
1.0×
2.6×
43.33%
—

Twelve months to Sep 30, 2026 · derived

Price

$24.9844.33%$19.88past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$780.57MFY 2025
$780.57M0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$780,567,000reported
FY 20242024-12-31$631,449,000reported
FY 20232023-12-31$566,767,000reported
FY 20222022-12-31$463,933,000reported
FY 20212021-12-31$276,868,000reported
FY 20202020-12-31$310,016,000reported
FY 20192019-12-31$296,701,000reported
FY 20182018-12-31$280,413,000reported
FY 20172017-12-31$28,476,000reported
FY 20162016-12-31$1,711,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$25.10M$25.10M—31.75M sh+0.9%7.7%
FY2024—$60.03M$60.03M—31.49M sh−1.5%29.5%
FY2023—$75.00M$75.00M—31.96M sh−6.2%27.3%
FY2022—$14.06M$14.06M—34.07M sh+2.1%11.5%
FY2021—$47.86M$47.86M—33.38M sh−4.0%47.1%

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Nucynta ER · FY2018 · $81.11MOther · FY2018 · $199.30MFY2019Nucynta ER · FY2019 · $74.01MOther · FY2019 · $222.69MFY2020Nucynta ER · FY2020 · $65.71MOther · FY2020 · $244.30MFY2021Nucynta ER · FY2021 · $70.94MOther · FY2021 · $205.93MFY2022Belbuca · FY2022 · $126.46MNucynta ER · FY2022 · $72.42MOther · FY2022 · $265.05MFY2023Belbuca · FY2023 · $182.10MXtampza ER · FY2023 · $177.37MNucynta IR · FY2023 · $108.15MNucynta ER · FY2023 · $82.65MSymproic and other · FY2023 · $16.50MNucynta ER · FY2023 · $82.65MOther · FY2023 · $302.02MFY2024Belbuca · FY2024 · $211.27MXtampza ER · FY2024 · $191.33MJornay PM · FY2024 · $37.24MNucynta IR · FY2024 · $100.74MNucynta ER · FY2024 · $75.77MSymproic and other · FY2024 · $15.10MNucynta ER · FY2024 · $75.77MOther · FY2024 · $307.17MFY2025Belbuca · FY2025 · $221.65MXtampza ER · FY2025 · $199.31MJornay PM · FY2025 · $148.86MNucynta IR · FY2025 · $115.31MNucynta ER · FY2025 · $80.99MSymproic and other · FY2025 · $14.45M
LineFY2025ShareChange
Belbuca$221.65M28%+4.9%
Xtampza ER$199.31M26%+4.2%
Jornay PM$148.86M19%+299.7%
Nucynta IR$115.31M15%+14.5%
Nucynta ER$80.99M10%+6.9%
Symproic and other$14.45M1.9%−4.3%
Nucynta ER———
Other———
Total$780.57M

From the 10-K filed Feb 26, 2026COLL

Pharmaceutical preparations

Collegium Pharmaceutical, Inc is the 41st largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR